First Author: A.Khattab EGYPT
Co Author(s): M. Torkey A. Saeed A.R. Ellakkanny 0 0 0 0 0 0 0 0 0
Back to previous
To evaluate the outcomes of Intravitreal Bevacizumab (IVB) mono-therapy compared with conventional laser therapy in preterm infants with stage III and plus disease retinopathy of prematurity (ROP) who had zone I or II posterior disease.
Mansoura University Pediatric Hospital.
This is a prospective randomized comparative interventional pilot study. Twelve eyes of sex preterm infants suffering from ROP were included. All eyes had bilateral stage III ROP with “plus disease” affecting zone I or zone II posterior. No eyes with any stage of retinal detachment or congenital ocular anomaly were in¬cluded. Data were collected for each baby regarding gestational age, birth weight, postmenstrual age at which ROP was detected, sex, single or multiple pregnancy and the affected zone. Infants were assigned to receive IVB in their right eyes and conventional laser therapy in their left eyes. Follow up period was 6 months following treatment.
The study included two females and four males. The gestational ages ranged from 26 to 30 week (mean = 28 weeks), and the birth weights ranged from 750 to 1100 g (mean = 904.2 gram). The postmenstrual age at which ROP was detected ranged between 34 and 39 week (mean = 36.5 week). All the twelve eyes had stage III ROP with plus disease, six eyes had Zone I disease while the other six eyes had zone II posterior. Regression of Neovascularization occurred in all 12 eyes following both treatment modalities and remained stable during follow-up. No local or systemic side effects of bevacizumab were observed, and no further treatment was necessary.
IVB injection seems to be as effective as conventional laser in treating stage III ROP. It provides the advantages of preservation of peripheral visual field, less myopia induction, and the complete peripheral retinal vascularization.